文献速递肿瘤 PET/CT甲状腺核医学

68Ga-DOTA-Bombesin PET/CT与18F-FDG PET/CT在乳腺癌分期中的临床价值比较

Clinical Value of 68 Ga-DOTA-Bombesin PET/CT Compared With 18 F-FDG PET/CT in the Staging of Breast Cancer.
PubMed 文献 · Clin Nucl Med · 2026-06-18

Bombesin显示原发灶灵敏度92.3%,淋巴结分期特异度100%高于FDG的53.8%,且摄取与雌激素受体阳性及低Ki-67指数相关。

要点

  • Bombesin淋巴结分期特异度100%优于FDG的53.8%。
  • Bombesin原发灶灵敏度92.3%,与FDG的84.6%相当。
  • Bombesin摄取与ER阳性及低Ki-67指数显著相关。

核心结论

  • 68Ga-DOTA-Bombesin PET/CT提供受体特异性成像,在激素受体阳性和低增殖肿瘤中与18F-FDG互补。

主要发现

  • Bombesin显示原发灶灵敏度92.3%,FDG为84.6%。
  • Bombesin淋巴结分期特异度100%,FDG为53.8%。
  • Bombesin摄取与雌激素受体阳性及较低Ki-67指数相关(P<0.05)。
  • 在4例远处转移患者中,FDG检测肝和肺病灶,Bombesin识别额外的骨和腹膜病灶。
  • Bombesin的肝脏和骨髓生理摄取较低,血池摄取较高。

关键数值与推荐

  • 原发灶灵敏度:Bombesin 92.3%,FDG 84.6%。
  • 淋巴结分期特异度:Bombesin 100%,FDG 53.8%。
  • Bombesin摄取与ER阳性及低Ki-67指数相关(P<0.05)。

临床怎么用

  • 在乳腺癌分期中,Bombesin PET/CT可作为FDG的补充,尤其适用于激素受体阳性、低增殖肿瘤的淋巴结评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To prospectively evaluate the diagnostic performance of 68 Ga-DOTA-Bombesin PET/CT compared with 18 F-FDG PET/CT in breast cancer (BC), emphasizing its utility across molecular subtypes and nodal staging. PATIENTS AND METHODS: Twenty-four patients with biopsy-proven BC who underwent both 68 Ga-DOTA-Bombesin and 18 F-FDG PET/CT were included. Imaging findings were analyzed on a per-lesion and per-patient basis for primary tumor detection, axillary lymph-node involvement, and distant metastases. Quantitative parameters (SUVmax, MTV, and tumor-to-background ratios) were compared across histopathologic and receptor subgroups, with histopathology as the reference standard. RESULTS: 68 Ga-DOTA-Bombesin visualized 92.3% of primary tumors, achieving comparable sensitivity to 18 F-FDG (84.6%) but higher specificity in nodal staging (100% vs. 53.8%). Bombesin uptake correlated strongly with estrogen receptor positivity and a lower Ki-67 index ( P <0.05). In a limited number of patients with distant metastases (n=4), FDG appeared to detect hepatic and pulmonary lesions, whereas Bombesin identified additional osseous and peritoneal lesions. Physiological uptake was lower in the liver and bone marrow but higher in the blood pool for Bombesin. Emerging antagonist data indicate further improvements in tumor-to-background ratios and potential theranostic applications. CONCLUSIONS: 68 Ga-DOTA-Bombesin PET/CT provides a receptor-specific imaging approach in BC, showing complementary strengths to 18 F-FDG, particularly in hormone-receptor-positive and low-proliferation tumors. Its superior nodal specificity and theranostic potential support further evaluation of GRPR-targeted imaging and therapy in personalized BC management.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Baloglu MC, Şahin R, Tosunoglu Z, et al. Clinical Value of 68 Ga-DOTA-Bombesin PET/CT Compared With 18 F-FDG PET/CT in the Staging of Breast Cancer. Clin Nucl Med. 2026. PMID: 42305081. doi:10.1097/RLU.0000000000006582

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。